For patients who received a letter on improperly disclosed information by a claims processing vendor, read more.

Excellence is just the beginning.

Translate

French German Italian Portuguese Russian

Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors

Clinical Trial Title: 
Phase 2 trial of response-based radiation therapy for patients with localized central nervous system germ cell tumors (CNS GCT).
Clinical Trial Protocol ID: 
14011406-CA01
Clinical Trial Investigator Name: 
Mary Lou Schmidt, MD
Clinical Trial Protocol Description: 

To determine, as measured by the 3-year progression free survival rate and patterns of failure, whether simplified chemotherapy followed by dose-reduced radiation therapy is effective for treating children and young adults (ages 3 to < 21 years) with localized  primary central nervous system (CNS) germinoma who present with serum and/or CSF human chorionic gonadotropin-beta (hCGI3) < 50miU/ml.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Are between 3 and 21 years of age at the time of study enrollment.
  • Have been newly diagnosed with localized primary CNS NGGCT (Stratum  1) or localized primary CNS germinoma (Stratum 2). Germ cell tumors located in the suprasellar  pineal, bifocal (pineal + suprasellar) and ventricles are eligible. Tumors present  in the above mentioned locations and with unifocal parenchymal extension are eligible.

This is a partial list of elgibility requirements.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 355-0741
Contact Name: 
Nitin Sane